AU2017299374B2 - Formulations of polyalkylene oxide-asparaginase and methods of making and using the same - Google Patents

Formulations of polyalkylene oxide-asparaginase and methods of making and using the same Download PDF

Info

Publication number
AU2017299374B2
AU2017299374B2 AU2017299374A AU2017299374A AU2017299374B2 AU 2017299374 B2 AU2017299374 B2 AU 2017299374B2 AU 2017299374 A AU2017299374 A AU 2017299374A AU 2017299374 A AU2017299374 A AU 2017299374A AU 2017299374 B2 AU2017299374 B2 AU 2017299374B2
Authority
AU
Australia
Prior art keywords
composition
asparaginase
polyalkylene oxide
concentration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017299374A
Other languages
English (en)
Other versions
AU2017299374A1 (en
Inventor
Gianfranco Fornasini
Christopher Phillips
Nadejda SOUKHAREVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Servier IP UK Ltd
Original Assignee
Servier IP UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60992770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017299374(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier IP UK Ltd filed Critical Servier IP UK Ltd
Publication of AU2017299374A1 publication Critical patent/AU2017299374A1/en
Application granted granted Critical
Publication of AU2017299374B2 publication Critical patent/AU2017299374B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2017299374A 2016-06-01 2017-06-01 Formulations of polyalkylene oxide-asparaginase and methods of making and using the same Active AU2017299374B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662344256P 2016-06-01 2016-06-01
US201662344249P 2016-06-01 2016-06-01
US201662344252P 2016-06-01 2016-06-01
US62/344,252 2016-06-01
US62/344,249 2016-06-01
US62/344,256 2016-06-01
PCT/US2017/035461 WO2018017190A2 (en) 2016-06-01 2017-06-01 Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Publications (2)

Publication Number Publication Date
AU2017299374A1 AU2017299374A1 (en) 2018-12-20
AU2017299374B2 true AU2017299374B2 (en) 2021-05-27

Family

ID=60992770

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017299374A Active AU2017299374B2 (en) 2016-06-01 2017-06-01 Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Country Status (32)

Country Link
US (3) US12343387B2 (cg-RX-API-DMAC7.html)
EP (2) EP3463308B2 (cg-RX-API-DMAC7.html)
JP (2) JP7109427B2 (cg-RX-API-DMAC7.html)
KR (3) KR102473887B1 (cg-RX-API-DMAC7.html)
CN (1) CN109640961B (cg-RX-API-DMAC7.html)
AU (1) AU2017299374B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018074823B1 (cg-RX-API-DMAC7.html)
CA (1) CA3026070A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003418A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018013753A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124980T1 (cg-RX-API-DMAC7.html)
DK (1) DK3463308T3 (cg-RX-API-DMAC7.html)
ES (1) ES2905874T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20212027T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057856T2 (cg-RX-API-DMAC7.html)
IL (2) IL312621A (cg-RX-API-DMAC7.html)
LT (1) LT3463308T (cg-RX-API-DMAC7.html)
MX (2) MX388814B (cg-RX-API-DMAC7.html)
MY (1) MY198474A (cg-RX-API-DMAC7.html)
NZ (1) NZ788906A (cg-RX-API-DMAC7.html)
PH (1) PH12018502540A1 (cg-RX-API-DMAC7.html)
PL (1) PL3463308T3 (cg-RX-API-DMAC7.html)
PT (1) PT3463308T (cg-RX-API-DMAC7.html)
RS (1) RS62979B1 (cg-RX-API-DMAC7.html)
RU (1) RU2758796C2 (cg-RX-API-DMAC7.html)
SA (1) SA518400557B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201810685WA (cg-RX-API-DMAC7.html)
SI (1) SI3463308T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200049T1 (cg-RX-API-DMAC7.html)
UA (1) UA123020C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018017190A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201807943B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
KR20210109551A (ko) * 2018-12-07 2021-09-06 옥스포드 유니버시티 이노베이션 리미티드 링커
PE20220492A1 (es) * 2018-12-24 2022-04-07 Gennova Biopharmaceuticals Ltd Composicion liofilizada de pegaspargasa
BR112023019862A2 (pt) * 2021-04-06 2023-11-07 Jazz Pharmaceuticals Ireland Ltd Formulações de l-asparaginase
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法
CN119326875A (zh) * 2024-12-23 2025-01-21 中国人民解放军总医院第三医学中心 L-ASNase在制备治疗膀胱癌药物中的应用及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0875252A2 (en) * 1997-04-28 1998-11-04 Eli Lilly And Company Activated protein C formulations
CN102138909A (zh) * 2010-12-30 2011-08-03 常州千红生化制药股份有限公司 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液
US20160060613A1 (en) * 2009-07-06 2016-03-03 Alize Pharma Ii Sas Pegylated L-asparaginase

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
JPS58183626A (ja) 1982-04-21 1983-10-26 Nippon Oil Co Ltd 白血病治療用ｌ−アスパラギナ−ゼ固定化剤
US4729957A (en) 1984-12-13 1988-03-08 The United States Of America As Represented By The Department Of Health And Human Services Process for manufacture of L-asparaginase from erwinia chrysanthemi
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
TW197439B (cg-RX-API-DMAC7.html) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
EP0642586A4 (en) 1992-05-21 1995-11-29 Penn State Res Found CULTURAL -i (TAXUS) FABRIC AS A SOURCE OF TAXOL, RELATED TAXANS AND OTHER NEW ANTI-TUMOR / ANTI-VIRAL SUBSTANCES (01/20/94).
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US6087151A (en) 1995-02-08 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo DNA coding for mammalian L-asparaginase
WO1996033212A1 (fr) 1995-04-21 1996-10-24 Teikoku Hormone Mfg. Co., Ltd. Nouveaux derives peptidiques
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6537547B1 (en) 1996-06-07 2003-03-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptides having L-asparaginase activity
AU3740997A (en) 1996-08-26 1998-03-19 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
CA2295980A1 (en) 1997-06-09 1998-12-17 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
US6991788B1 (en) 1997-06-09 2006-01-31 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
SK182599A3 (en) 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US5854051A (en) 1997-09-15 1998-12-29 Heska Corporation Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
AU741433B2 (en) 1997-10-08 2001-11-29 Bio Research Corporation Of Yokohama Taxoid derivatives and process for producing the same
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
KR100420642B1 (ko) 1998-03-26 2004-03-02 쉐링 코포레이션 Ｐｅｇ-인터페론 알파 결합체의 보호에 사용되는 제형
ATE365052T1 (de) * 1999-02-22 2007-07-15 Univ Connecticut Neue albuminfreie faktor viii formulierungen
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7910661B2 (en) * 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
MX2009000284A (es) 2006-06-30 2009-01-26 Enzon Pharmaceuticals Inc Hospedero recombinante para produccion de l-asparaginasa ii.
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008240796A1 (en) 2007-04-20 2008-10-30 Dsm Ip Assets B.V. Asparaginase enzyme variants and uses thereof
FI20070455A0 (fi) 2007-06-08 2007-06-08 Reagena Ltd Oy Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
SI2585104T1 (sl) * 2010-06-25 2019-11-29 Shire Human Genetic Therapies Postopki in sestavki za dostavo arilsulfataze A
WO2012028945A2 (en) 2010-09-01 2012-03-08 Indian Institute Of Technology, Dehli Mutants of l-asparagine
RU2441914C1 (ru) 2010-10-06 2012-02-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN102657852A (zh) * 2012-05-22 2012-09-12 范铭琦 重组沃氏菌天门冬酰胺酶药物组合物及其制备法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0875252A2 (en) * 1997-04-28 1998-11-04 Eli Lilly And Company Activated protein C formulations
US20160060613A1 (en) * 2009-07-06 2016-03-03 Alize Pharma Ii Sas Pegylated L-asparaginase
CN102138909A (zh) * 2010-12-30 2011-08-03 常州千红生化制药股份有限公司 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEMA SANDEEO ET AL, Excipients: Their Role in Parenteral Dosage Forms, ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY, PAGES 137-172, (2000-01-01), ISBN 978-0-8247-2818-2 *

Also Published As

Publication number Publication date
SI3463308T1 (sl) 2022-04-29
KR20220165820A (ko) 2022-12-15
JP7109427B2 (ja) 2022-07-29
RU2018146395A3 (cg-RX-API-DMAC7.html) 2020-07-09
EP3463308A2 (en) 2019-04-10
BR112018074823B1 (pt) 2024-02-27
RS62979B1 (sr) 2022-03-31
US20250242004A1 (en) 2025-07-31
DK3463308T3 (da) 2022-01-31
EP3463308B2 (en) 2026-01-07
ZA201807943B (en) 2022-09-28
US20190240300A1 (en) 2019-08-08
WO2018017190A3 (en) 2018-03-01
NZ749069A (en) 2025-02-28
HRP20212027T1 (hr) 2022-04-01
KR102783452B1 (ko) 2025-03-19
SG11201810685WA (en) 2018-12-28
MY198474A (en) 2023-08-31
CL2018003418A1 (es) 2019-05-24
PH12018502540A1 (en) 2019-04-08
RU2758796C2 (ru) 2021-11-01
HUE057856T2 (hu) 2022-06-28
SMT202200049T1 (it) 2022-03-21
JP2019521179A (ja) 2019-07-25
KR102473887B1 (ko) 2022-12-06
PL3463308T3 (pl) 2022-03-14
SA518400557B1 (ar) 2024-02-29
UA123020C2 (uk) 2021-02-03
EP4019007A1 (en) 2022-06-29
US12343387B2 (en) 2025-07-01
MX388814B (es) 2025-03-20
IL312621A (en) 2024-07-01
ZA202202259B (en) 2022-11-30
JP2022071060A (ja) 2022-05-13
MX2021015544A (es) 2022-02-23
PT3463308T (pt) 2022-03-11
CN109640961B (zh) 2021-11-02
US20240108701A1 (en) 2024-04-04
EP3463308A4 (en) 2019-12-18
CY1124980T1 (el) 2023-01-05
AU2017299374A1 (en) 2018-12-20
KR20190015366A (ko) 2019-02-13
MX2018014916A (es) 2019-07-18
CO2018013753A2 (es) 2019-01-18
EP3463308B1 (en) 2021-12-01
LT3463308T (lt) 2022-02-10
CN109640961A (zh) 2019-04-16
IL263349A (en) 2019-01-31
NZ788906A (en) 2025-07-25
IL263349B1 (en) 2024-06-01
CA3026070A1 (en) 2018-01-25
IL263349B2 (en) 2024-10-01
KR20230162139A (ko) 2023-11-28
WO2018017190A2 (en) 2018-01-25
RU2018146395A (ru) 2020-07-09
ES2905874T3 (es) 2022-04-12
BR112018074823A2 (pt) 2019-03-06

Similar Documents

Publication Publication Date Title
US20240108701A1 (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
JP4785816B2 (ja) 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法
KR101221680B1 (ko) 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성 솔루션과 준비방법
JP2016196636A (ja) 誘導体化超分岐ポリグリセロール類
JP2023534504A (ja) ポリマー組み合わせ調製物を含む調製物及び組成物
EP3056208B1 (en) Immunopotentiator
CN101287474A (zh) 使用乙酰透明质酸的治疗方案
HK40076514A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
HK40006539B (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
HK40006539A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
EA040430B1 (ru) Препараты полиалкиленоксид-аспарагиназы и способы их получения и применение
HK40007007B (zh) 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
EP3429616B1 (en) Compositions for the treatment and prevention of hoof and claw diseases
HK40007007A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
Aghamiri et al. Preparation and Evaluation of Sodium Alginate Nanoparticles Containing Recombinant Diphtheria Toxoid (CRM197) and their Immunogenicity in Mice

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)